Abstract： Objective To evaluate the efficacy and safety of nueleoside(s)analog in patients with decompensated cirrhosis related to hepatitis B virus with different levels of HBV-DNA loads.Methods One hundred and forty-three patients with decompensated cirrhosis of hepatitis B vires infection were divided into low10e5copies/mL)(97cases).21 cases in low-level group and 52 cases in high-level group were treated with nucleoside(s)analog and liver protective drugs as treatment group,other 25 cases in low-level group and 47 cases in high-level group were treated with liver protective drugs as control group.Supportive treatment and symptomatic treatment were given in four groups.Results In low-level HBV DNA patients,the decrease of AST,the increase of ALB and CHE and the loss of HBV-DNA in treatment group were significant higher than that in control group at week 48(P<0.05).In the high-level HBV-DNA patients,the decrease of AST,ALT and TBil and the increase of ALB and CHE,the loss of HBV-DNA and HBeAg wag higher in treatment group than that in control group(P<0.05).Conclusion nucleoside analog therapy could improve the liver function and slow down the progress of the disease in patients with decompensated HBV cirrhosis with different levels of HBV-DNA load.